UBS ETRACS Gold Shares Covered Call ETN GLDI
Nov 9, 2026, 2:27 PM EST
- YTD
- -20.03%
- 1 year
- -17.87%
Discussion (3)
Sign in to join the discussion
VICKY HANUKA GLDI 2 years ago #1
About Destiny Tech100
Destiny's flagship offering, the Destiny Tech100, will be a publicly-listed portfolio of 100 of the top venture-backed private technology companies, providing everyday investors access to many of the world's most exciting private businesses.
Current Tech100 holdings include: SpaceX, OpenAI, Epic Games, Discord, Superhuman, and Stripe. For a comprehensive list of holdings, visit the fund website www.destiny.xyz/tech100.
Image for Press Release 1867753
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327776952/en/
VICKY HANUKA GLDI 2 years ago #2Don’t miss the opportunity going crazy
About Destiny Tech100
Destiny's flagship offering, the Destiny Tech100, will be a publicly-listed portfolio of 100 of the top venture-backed private technology companies, providing everyday investors access to many of the world's most exciting private businesses.
Current Tech100 holdings include: SpaceX, OpenAI, Epic Games, Discord, Superhuman, and Stripe. For a comprehensive list of holdings, visit the fund website www.destiny.xyz/tech100.
Image for Press Release 1867753
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327776952/en/
VICKY HANUKA GLDI 3 years ago #3$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.